Skip to main content
Journal cover image

Professional perspectives about pharmacogenetic testing and managing ancillary findings.

Publication ,  Journal Article
Haga, SB; Tindall, G; O'Daniel, JM
Published in: Genet Test Mol Biomarkers
January 2012

AIMS: Pharmacogenetic (PGx) tests, intended to inform therapeutic decision making through prediction of patient likelihood to respond to or experience an adverse effect from a specific treatment, may also generate ancillary, or incidental, disease information unrelated to the purpose for which the test was ordered. To assess attitudes toward PGx testing, ancillary disease risk information, and related clinical issues, we conducted a series of focus groups among health professionals. RESULTS: Twenty-one primary care and genetics professionals from Durham, NC, were recruited to participate in three focus groups (two of primary care professionals [PCPs] and one of geneticists). Overall, interest in PGx testing was positive, though enthusiasm was reserved among PCPs due to concerns about clinical utility, insurance coverage, delay of treatment, and ability to communicate and interpret ancillary disease risk information. Although many PCPs felt an obligation to disclose information about ancillary disease risk, geneticists did not believe that it was always necessary, noting the complexities of genetic risk results such as incomplete penetrance. CONCLUSION: This pilot study found that health professionals' interest in the use of PGx testing was limited by concerns about the lack of evidence of clinical utility and their ability to interpret and communicate ancillary disease risk information to patients. Additional educational resources, access to genetic specialists, and clear clinical guidelines about the use of PGx testing would greatly facilitate appropriate use of testing.

Duke Scholars

Published In

Genet Test Mol Biomarkers

DOI

EISSN

1945-0257

Publication Date

January 2012

Volume

16

Issue

1

Start / End Page

21 / 24

Location

United States

Related Subject Headings

  • Young Adult
  • Professional Role
  • Practice Guidelines as Topic
  • Pharmacogenetics
  • Middle Aged
  • Male
  • Incidental Findings
  • Humans
  • Genetics & Heredity
  • Genetic Counseling
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haga, S. B., Tindall, G., & O’Daniel, J. M. (2012). Professional perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers, 16(1), 21–24. https://doi.org/10.1089/gtmb.2011.0045
Haga, Susanne B., Genevieve Tindall, and Julianne M. O’Daniel. “Professional perspectives about pharmacogenetic testing and managing ancillary findings.Genet Test Mol Biomarkers 16, no. 1 (January 2012): 21–24. https://doi.org/10.1089/gtmb.2011.0045.
Haga SB, Tindall G, O’Daniel JM. Professional perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers. 2012 Jan;16(1):21–4.
Haga, Susanne B., et al. “Professional perspectives about pharmacogenetic testing and managing ancillary findings.Genet Test Mol Biomarkers, vol. 16, no. 1, Jan. 2012, pp. 21–24. Pubmed, doi:10.1089/gtmb.2011.0045.
Haga SB, Tindall G, O’Daniel JM. Professional perspectives about pharmacogenetic testing and managing ancillary findings. Genet Test Mol Biomarkers. 2012 Jan;16(1):21–24.
Journal cover image

Published In

Genet Test Mol Biomarkers

DOI

EISSN

1945-0257

Publication Date

January 2012

Volume

16

Issue

1

Start / End Page

21 / 24

Location

United States

Related Subject Headings

  • Young Adult
  • Professional Role
  • Practice Guidelines as Topic
  • Pharmacogenetics
  • Middle Aged
  • Male
  • Incidental Findings
  • Humans
  • Genetics & Heredity
  • Genetic Counseling